NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.

The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...

Severe mpox and long-term sequelae such as severe scarring were more likely to occur among HIV-positive patients with detectable viral loads and low CD4 counts.

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

The mpox virus is currently rampaging through the Democratic Republic of Congo, with 2,000 cases since the start of the year ...

Health officials have raised alarms over a newly identified, highly transmissible mpox variant, suspected of driving a surge ...

The number of mpox cases in Africa increased leading up to the first mpox declaration of a Public Health Emergency of ...

“The data presented here represent an important step forward in the evaluation of tecovirimat and in our understanding of mpox.” STOMP was led by Dr. Wilkin, Dr. Fischer, Jason ...

The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...

recently presented data demonstrating that tecovirimat did not improve mpox resolution. The results from STOMP (Study of Tecovirimat for Mpox, also known as A5418) were shared as the oral ...